Application of different configurations of glp-1 similar peptide modified dimers and their preparation methods in the treatment of type ii diabetes

A GLP-1, homodimer technology, applied in chemical instruments and methods, medical preparations containing active ingredients, peptides, etc., can solve the problems of natural GLP1 effective, obvious side effects, etc., to protect pancreatic function, increase The time of hypoglycemic effect and the effect of promoting technology upgrading

Active Publication Date: 2021-01-19
深圳纳福生物医药有限公司
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the side effects are obvious
[0012] GLP-1 analog studies still need to be optimized, as current long-acting activators have proven less effective than Liraglutide or native GLP1 in terms of specific activity (lowering glucose in milligrams), dosing, weight loss, and side effects , for example, in the 26-week trial, Albiglutide lost 0.6 kg compared with Liraglutide's 2.2 kg, and the dulaglutide group lost 2.9 kg compared to 3.6 kg for Liraglutide.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of different configurations of glp-1 similar peptide modified dimers and their preparation methods in the treatment of type ii diabetes
  • Application of different configurations of glp-1 similar peptide modified dimers and their preparation methods in the treatment of type ii diabetes
  • Application of different configurations of glp-1 similar peptide modified dimers and their preparation methods in the treatment of type ii diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The preparation of embodiment 1 monomer peptide and dimer

[0056] 1. Monomer peptide solid-phase synthesis process: Manual solid-phase peptide synthesis operation steps.

[0057] 1. Resin swelling: Put dichloro resin (dichlorobenzyl resin for C-terminal carboxyl group) or amino resin (amino resin for C-terminal amidation sequence) (purchased from Tianjin Nankai Synthetic Technology Co., Ltd.) into In the reaction pot, add dichloromethane (DCM, Dikma Technologies Inc.) 15ml / g resin, shake for 30min. SYMPHONY 12-channel polypeptide synthesizer (SYMPHONY model, software Version.201, Protein Technologies Inc.).

[0058] 2. Connect the first amino acid: Remove the solvent through sand core suction filtration, add 3 times the mole of the first Fmoc-AA amino acid at the C-terminal (all Fmoc-amino acids are provided by Suzhou Tianma Pharmaceutical Group Fine Chemicals Co., Ltd.), and then Add 10-fold molar amounts of 4-dimethylaminopyridine (DMAP) and N,N'-dicyclohexylcarbod...

Embodiment 2

[0083] Example 2 Persistence of the hypoglycemic effect of the GLP-1 monomers and homodimers (G2-9 and 2G2-9 series) of the present invention:

[0084] 1. Experimental method: Normal KM mice were purchased from the Animal Center of Guangdong Province for glucose tolerance test (OGTT) to screen the hypoglycemic activity and persistence of drugs. According to the undifferentiated fasting blood glucose, male Kunming mice (5 weeks old) were divided into multiple groups (NaCl-PB group, Liraglutide group, monomer G2-G9 series and dimer 2G2~2G9 series group) (n=6) . After two rounds of 14-hour feeding-10-hour fasting adaptation period, KM mice were tested for glucose tolerance immediately after each 10-hour fasting. Thirty minutes after subcutaneous injection of the same dose of monomeric or dimer peptides on the back, the mice were orally gavaged with 5% glucose solution, and the blood glucose value of the rat tail was accurately measured at 35 minutes. Blood glucose meters and bl...

Embodiment 3 2

[0096] Embodiment 3 dimer is to the therapeutic effect of type 2 diabetes model

[0097] 1. Construction of type II diabetes (T2D) mouse model

[0098] C57Bl6 / J mice were placed in an SPF-level environment with standard diet and had free access to water. All experiments were performed in accordance with the institutional guidelines for the ethics and use of experimental animals. After feeding with a standard diet for 10 days, 5-week-old C57B16 / J male mice were divided into 6 groups: NaCl-PB, T2D model control group, Liraglutiade, low-middle-high dimer peptide 2G3 or 2G1 group. NaCl-PB group is blank control and T2D model control group is T2D model control, they are injected with NaCl-PB solution. The T2D model group was fed a 60kcal% high-fat diet (D12492, Changzhou Shuyishuerbiotechnology Co., Ltd.) until the end of the experiment, and the blank control group maintained a standard diet until the end of the experiment. The establishment method of the diabetes model: After f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides the application of novel glucagon peptide 1 fatty acid modified or non-modified dimers with different configurations in the treatment of type II diabetes mellitus for pancreas protection or hypoglycemic effect. The dimer of the present invention is formed by linking two identical cysteine-containing GLP-1 monomers through a disulfide bond formed by cysteine ​​oxidation. The H-type GLP-1 homodimer of the present invention (forms a disulfide bond inside the peptide chain) significantly increases the duration of hypoglycemic effect of the GLP-1 dimer without reducing the activity, and the GLP-1 provided is similar The activity of the dimer in the body lasts up to 19 days, which is significantly longer than that of the positive control drug liraglutide, which is 3 days, or compared with the long-acting GLP1 analog peptides that have been reported so far, which greatly promotes the long-term The technical progress of effective GLP1 drugs has facilitated their clinical application and promotion. At the same time, the U-shaped homodimer (forming a disulfide bond at the C-terminus of the peptide chain) does not affect blood sugar, but it can obviously protect exocrine cells such as pancreatic acini and ducts, and protect the function of the pancreas.

Description

technical field [0001] The invention belongs to the field of medicine and biology, and specifically relates to the preparation of various human novel GLP 1-like peptide monomers or homodimers and their application in treating diabetes. Background technique [0002] Glucagon-like peptide 1 (GLP 1) from proglucagon protein is a 30 amino acid residue incretin-like peptide that is released by intestinal L cells upon nutrient intake. It enhances pancreatic β-cell insulin secretion, increases insulin expression and peripheral glucose utilization, inhibits β-cell apoptosis, promotes satiety and β-cell regeneration, reduces glucagon secretion, and delays gastric emptying. These multiple effects make GLP1 receptor agonists significant in the treatment of type 2 diabetes. Currently FDA-approved GLP-1 analogues include Liraglutide (liraglutide) administered once a day, Exenatide administered twice a day and Albiglutide, Dulaglutide, Exenatide LAR, Lixisenatide, Semaglutide administere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/605C07K19/00A61K38/26A61P3/10
CPCC07K14/605A61P3/10C07K2319/00A61K38/00C07K2319/31A61K38/26
Inventor 唐松山罗群张旭东董玉霞唐婧晅杨莉李玉华葛平戴小敏
Owner 深圳纳福生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap